Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 19/20 | 1.00 |
| ▸ | CTNNB1 | P35222 | 2/20 | 1.00 |
| ▸ | TCF7 | P36402 | 2/20 | 1.00 |
| ▸ | BCL9 | O00512 | 1/20 | 1.00 |
| ▸ | TCF4 | P15884 | 1/20 | 1.00 |
| ▸ | CREBBP | Q92793 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19833048 | 1.00 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL13744871 | 1.00 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL4865605 | 1.00 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL178745 | 1.00 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL15677335 | 1.00 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL29352986 | 1.00 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL15677334 | 0.96 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL18699677 | 0.96 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL19833044 | 0.94 | CLPP (0.92) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL20752946 | 0.94 | CLPP (0.92) | CLPPCTNNB1TCF7BCL9TCF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240240155-A1 | Organoid-Derived Monolayers and Uses Thereof | HUB ORGANOIDS IP B.V. (NL) | 2024-07-18 | — | — | US | disclosed |
| US-20240240155-A1 | Organoid-Derived Monolayers and Uses Thereof | HUB ORGANOIDS IP B.V. (NL) | 2024-07-18 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-20210047618-A1 | Improved Differentiation Method | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2021-02-18 | — | — | US | disclosed |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-7345040-B2 | Reverse-turn mimetics and compositions and methods relating thereto | MYRIAD GENETICS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20050250780-A1 | Reverse-turn mimetics and compositions and methods relating thereto | MYRIAD GENETICS, INCORPORATED (US) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | CLPP 571/4885CTNNB1 920/4885TCF7 784/4885 |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | CLPP 265/4885CTNNB1 1267/4885TCF7 1353/4885 |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | CLPP 265/4885CTNNB1 1267/4885TCF7 1353/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | CLPP 4176/4885CTNNB1 4431/4885TCF7 2990/4885 |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | CLPP 571/4885CTNNB1 920/4885TCF7 784/4885 |
| US-20050250780-A1 | Reverse-turn mimetics and compositions and methods relating thereto | TAC3, NTSR1, SCTR | CLPP 1827/4885CTNNB1 3010/4885TCF7 1058/4885 |
| US-20210047618-A1 | Improved Differentiation Method | VIPR2, IAPP, PROX1 | CLPP 4604/4885CTNNB1 1274/4885TCF7 590/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | CLPP 3159/4885CTNNB1 3914/4885TCF7 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.